Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A

• Үндсэн зохиолчид: Masato Bingo (Зохиогч), Katsuyuki Fukutake (Зохиогч), Kanae Togo (Зохиогч), Linghua Xu (Зохиогч), José Maria Jimenez Alvir (Зохиогч), Ian Winburn (Зохиогч), Toshiyuki Karumori (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Adis, Springer Healthcare, 2024-08-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract Background Treatment for haemophilia A has expanded from plasma-derived factor VIII (pdFVIII) and standard half-life (SHL) recombinant FVIII (rFVIII) to extended half-life (EHL) rFVIII and non-factor products that mimic FVIII activity. Objective To determine amounts of clotting factor conce...